<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9975">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05686239</url>
  </required_header>
  <id_info>
    <org_study_id>C07-03-02</org_study_id>
    <nct_id>NCT05686239</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)</brief_title>
  <official_title>An Adaptive, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Recognify Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Recognify Life Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to evaluate if the investigational drug, RL-007, can&#xD;
      improve the cognitive performance of subjects with schizophrenia. The main questions the&#xD;
      study aims to answer are:&#xD;
&#xD;
        1. Does RL-007 improve subjects performance in a set of cognitive tasks?&#xD;
&#xD;
        2. Which dose of RL-007 (20 mg or 40 mg) has a larger effect on cognitive performance?&#xD;
&#xD;
        3. How well do subjects tolerate RL-007?&#xD;
&#xD;
      In the study, subjects will perform the cognitive tasks at the beginning to get familiar with&#xD;
      the tasks. Then, subjects will be given either RL-007 or a placebo for 6 weeks and then&#xD;
      repeat the cognitive tasks. The researchers will compare the results at the end of the&#xD;
      treatment period to the baseline to see if there have been any changes in performance.&#xD;
&#xD;
      Additionally, several safety measures will be collected throughout the study (blood pressure,&#xD;
      physical exam, ECGs, etc) to evaluate if there are any side effects from taking RL-007.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, 3-arm, placebo-controlled, double-blinded clinical trial to evaluate&#xD;
      the efficacy, safety, and tolerability of RL-007 in subjects with stable schizophrenia. The&#xD;
      treatment period is 6 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 8, 2022</start_date>
  <completion_date type="Anticipated">November 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MATRICS Consensus Cognitive Battery (MCCB) neurocognitive composite</measure>
    <time_frame>6 weeks</time_frame>
    <description>change from baseline in composite of nine cognitive tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symbol Coding</measure>
    <time_frame>6 weeks</time_frame>
    <description>change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Speed of Processing domain of the MCCB</measure>
    <time_frame>6 weeks</time_frame>
    <description>change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Attention/Vigilance domain of the MCCB</measure>
    <time_frame>6 weeks</time_frame>
    <description>change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Working Memory domain of the MCCB</measure>
    <time_frame>6 weeks</time_frame>
    <description>change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Verbal Memory domain of the MCCB</measure>
    <time_frame>6 weeks</time_frame>
    <description>change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Visual Learning domain of the MCCB</measure>
    <time_frame>6 weeks</time_frame>
    <description>change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Reasoning and Problem-solving domain of the MCCB</measure>
    <time_frame>6 weeks</time_frame>
    <description>change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression - Severity (CGI-S)</measure>
    <time_frame>6 weeks</time_frame>
    <description>change from baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety measures</measure>
    <time_frame>6 weeks</time_frame>
    <description>Treatment Emergent Adverse Events</description>
  </other_outcome>
  <other_outcome>
    <measure>The Virtual Reality Functional Capacity Assessment Tool (VRFCAT)</measure>
    <time_frame>6 weeks</time_frame>
    <description>change from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>The Social Cognition domain of the MCCB</measure>
    <time_frame>6 weeks</time_frame>
    <description>change from baseline</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">234</enrollment>
  <condition>Cognitive Impairment Associated With Schizophrenia (CIAS)</condition>
  <condition>Cognitive Impairment</condition>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>RL-007 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral dosing three times per day (TID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RL-007 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral dosing three times per day (TID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral dosing three times per day (TID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RL-007</intervention_name>
    <description>investigational study drug</description>
    <arm_group_label>RL-007 20 mg</arm_group_label>
    <arm_group_label>RL-007 40 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo capsules matching the appearance and size of the active drug</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of schizophrenia, per Diagnostic and Statistical Manual (DSM) 5, with a&#xD;
             duration of at least 6 months&#xD;
&#xD;
          -  Positive and Negative Symptoms Severity Score (PANSS) of less than or equal to 80&#xD;
             (inclusive)&#xD;
&#xD;
          -  Currently treated on a single atypical antipsychotic (other than clozapine) at a&#xD;
             stable dose and clinically stable for at least 6 weeks before randomization&#xD;
&#xD;
          -  Clinical Global Impression - Severity score &lt; 5.&#xD;
&#xD;
          -  Body mass index (BMI) &lt;= 40.0 kg/m^2 at screening&#xD;
&#xD;
          -  Participant has reliable housing that is not expected to change during the study&#xD;
             period with no expected significant life events that could affect study outcomes&#xD;
             throughout entire study period.&#xD;
&#xD;
          -  Sufficient fluency in English to understand and complete study instructions and&#xD;
             assessments&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History of hospitalization for medical indication or psychiatric hospitalization&#xD;
             within 3 months prior to screening.&#xD;
&#xD;
          -  Participants who present a serious risk of suicide, as evidenced by a) &quot;yes&quot; on items&#xD;
             4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) and meeting these&#xD;
             criteria within the past 6 months, or b) posing a significant suicide risk in the&#xD;
             Investigator's judgement.&#xD;
&#xD;
          -  Participants who present a risk of serious harm to others, as evidence by any history&#xD;
             within the past 2 years and any expressed homicidal ideation (with or without plan).&#xD;
&#xD;
          -  Current diagnosis of another major psychiatric disorder, intellectual disability, or&#xD;
             any major neurological disease, brain injury, epilepsy, or severe brain trauma.&#xD;
&#xD;
          -  Evidence or history of significant cognitive impairment, other than associated with&#xD;
             schizophrenia, that in the judgement of the Investigator or Sponsor would confound&#xD;
             interpretation of study data or prevent safe and satisfactory completion of the study&#xD;
             protocol.&#xD;
&#xD;
          -  Meets criteria for moderate to severe substance/drug abuse disorder (including&#xD;
             alcohol) per DSM-5 within the last 6 months prior to informed consent or a positive&#xD;
             alcohol breath test or urine test for drugs of abuse at either Screening or&#xD;
             Randomization Visits (except for benzodiazepines taken according to prescription and&#xD;
             as an ongoing, stable regimen).&#xD;
&#xD;
          -  Participant has undergone electroconvulsive therapy within the past 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Walker, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Recognify Life Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gary Walker, PhD</last_name>
    <phone>510-552-0136</phone>
    <email>cias2@recognify.life</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matt Pando, PhD</last_name>
    <phone>571-217-1255</phone>
    <email>cias2@recognify.life</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Collaborative Neuroscience Research</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Walling, PhD</last_name>
      <phone>714-799-7799</phone>
    </contact>
    <investigator>
      <last_name>David Walling, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>December 28, 2022</study_first_submitted>
  <study_first_submitted_qc>January 8, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2023</study_first_posted>
  <last_update_submitted>January 8, 2023</last_update_submitted>
  <last_update_submitted_qc>January 8, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

